It may be challenging to stay asleep if you have insomnia or sleep disorders. Insomniacs frequently have insufficient sleep or sleep of low quality. According to recent research, some pharmacological treatments for insomnia seem to work better than others. Some medications are more effective for short-term treatment, while others can have significant side effects.
Two popular sleep aid drugs commonly used to treat insomnia are Belsomra and Ambien. The U.S. Food and Drug Administration has approved Belsomra and Ambien (FDA). These drugs are Schedule IV controlled substances, as they pose the risk of abuse and dependence.
Belsomra is classified as an orexin receptor antagonist, whereas Ambien is a sedative-hypnotic. Even though both pills are for treating insomnia, are they the same? Which is more effective?
Ambien (zolpidem) is a non-benzodiazepine used in insomnia in adults. It improves sleep onset and duration of sleep by acting on GABA receptors. If you want to order Ambien online, you must have a prescription because Ambien is a controlled substance in the USA.
In contrast to conventional benzodiazepines, zolpidem is a selective agonist of the? 1 receptor of the GABA-A receptor complex. The elimination half-life of zolpidem is 2.5 hours. It is indicated for insomnia, migraine headaches, and various neurologic conditions.
Ambien works as a sedative-hypnotic, causing the GABA neurotransmitters to become active, slowing down the brain and the Central Nervous System (CNS). As a result of the reduced brain activity, you fall asleep quickly.
The first drug in the orexin inhibitor family, suvorexant (Belsomra), is an antagonist of both orexin receptors and provides a novel mechanism for treating insomnia. The medication enhances sleep by inhibiting the function of orexin. It has a 10-hour half-life. Treatment of insomnia in adults difficulty with sleep onset and maintenance
Belsomra is an orexin receptor antagonist. It promotes sleep by inhibiting the neuropeptides orexin A and orexin B, thereby promoting wakefulness. The perifornical lateral hypothalamus contains 70,000 orexin neurons communicating with other brain and spinal cord parts.
Dosing is crucial for medications that can reduce severe morbidity or extend life. If administered incorrectly, patients may be given the wrong doses due to human error or loss after administration. Therefore, optimizing the proper dose before a drug is approved for use in everyday medicine is necessary.
Ambien comes in extended-release, immediate-release, sublingual tablets, and oral sprays. Ambien has 5 and 10 mg tablets, while the extended-release is available in 6.25 mg and 12.5 mg pills. Take Ambien before bedtime, and the patient should have 7-8 hours of sleep. The initial dose for women is 5 mg, and 5 mg or 10 mg for men. The maximum dose of Ambien is 10 mg once daily.
Belsomra comes in 5 mg, 10 mg, 15 mg, and 20 mg tablets. It is recommended to take 10 mg daily by mouth 30 minutes before bedtime. One should have at least 7 hours to sleep after taking suvorexant. The maximum daily dose is 20mg.
Ambien |
Belsomra |
Daytime drowsiness |
Drowsiness |
Dizziness |
Dizziness |
Weakness |
Sleepiness |
Lightheadedness |
Abnormal dreams |
Tiredness |
Headache |
Stuffy nose, nasal irritation |
Cough |
Dry mouth, sore throat |
Allergic reaction |
Nausea |
Sleep paralysis |
Constipation, diarrhea |
Diarrhea |
Muscle pain, ataxia |
Muscle weakness |
Confusion, memory loss |
Upper respiratory tract infection |
Euphoria |
Suicidal thoughts |
Visual changes |
Hallucination |
Suvorexant considerably improves the quality and length of sleep when compared to zolpidem.
In addition to having better efficacy, suvorexant does not cause withdrawal symptoms when stopped compared to other available therapies for insomnia.
Suvorexant use may be superior to first-line therapy for some populations, including older people. In addition to contributing to falls, benzodiazepines frequently produce vertigo and loss of balance. Suvorexant's mechanism of action does not result in dizziness; as a result, there is a chance to reduce dangerous falls in older people.
Patients who are obese also frequently experience insomnia. Obese women experience slower clearance of suvorexant and greater peak levels than non-obese women. And this could have worse consequences for obese women.
A survey by Michelson and his colleagues examined the Safety and effectiveness of suvorexant over one year, followed by a two-month cessation phase. They found that suvorexant significantly improved Total Sleep Time, TSO (total time from lying in bed to sleep initiation), and other sleep quality measures throughout therapy compared to placebo.
In a randomized, double-blinded, placebo-controlled trial with adult male volunteers in a noise-simulated setting, Bettina and colleagues compared the effectiveness of suvorexant with zolpidem (a non-BZD). The total sleep time they were increased by 17 and 31 minutes with suvorexant 10 mg and 30 mg, respectively, compared to 11 minutes with zolpidem.
Additionally, zolpidem medication lowered REM sleep while suvorexant treatment boosted it. The trial demonstrated that adverse effects following suvorexant were more prevalent than side effects following zolpidem. It is due to differences in their pharmacological activity.
Precautions are necessary steps taken before administering a drug. This is done to prevent any undesirable effects after taking the medication.
Ambien and Belsomra should not be taken at the same time. It might raise the likelihood of unfavorable side effects.
People with insomnia experience significant adverse effects on their quality of life. Getting proper treatment can contribute to a happier and healthier lifestyle. Both Belsomra and Ambien are used to treat insomnia. Although both drugs are quite effective in treating sleep disorders, they both carry the risk of addiction and abuse.
It may be challenging to treat insomnia with difficulties falling and staying asleep. Unlike zolpidem, suvorexant does not affect GABA, and its mode of action differs from that of zolpidem. It decreases wakefulness rather than promoting sleep.
Evidence suggests that this medicine benefits patients with symptoms of chronic insomnia over the long term. A healthcare provider can determine the most effective drug by considering a patient's medical condition, history, and current medications.